DEGS1 and cancer: In order to determine whether the de novo pathway contributes to the increase of ceramides in cancer, gene expression of dihydroceramide desaturase 1 (DES-1), an enzyme that converts dihydroceramide to ceramide in the de novo pathway, was measured.